• Organization TypeService Providers
  • Staff501-1000
  • HeadquartersFrance
  • Founded2002

MedinCell

MedinCell is owned and operated by their talented employees who have come together from around the world to achieve their mission of Better Medicine for All. Through purposeful innovation, they aim to improve the treatments available to patients. And they believe that everyone should have access to best-in-class medication, so they focus on making their products available regardless of local economic conditions. To ensure access, they work on both for-profit and non-profit projects, in collaboration with highly valued partners ranging from big pharmas to physicians, from biotech firms to academics and foundations. Most importantly, their partners share their values based on trust and transparency. What they believe Innovation is worth nothing unless it’s shared. That’s why they develop new best-in-class therapeutic solutions which are globally accessible. They must work together to improve global health. That’s why their approach takes into consideration the needs of all stakeholders, from patients and clinicians to payers, from researchers to investors. Pricing for medications must be fair and adapted to local economic situations. That’s why they have designed flexible business models responding to global needs.   What they do Everyday their team works toward improving global health by developing new therapeutic solutions with greater worldwide access. With their network of partners, they are developing the next generation of best-in-class medicine. They’re breaking the barrier for LAI adoption BEPO®, their long-acting injectable (LAI), meets health challenges on a global scale. By addressing issues of compliance, development timelines, tolerance, and costs, BEPO® provides opportunities for their partners to collaborate with them to achieve better outcomes for patients worldwide. Superior controlled release Fine tuned release. Customized release profile, longer duration Quick development Precise formulations. Innovative in vitro model with real time analysis GMP ready Scaled up polymer production in place. Low polymer cost and efficient API usage increases affordability Patient and clinician friendly Subcutaneous or local treatment. Improved compliance due to sustained release formulations  
See more

Company Offices

  • France (headquarters)
  • Jacou
  • 3 rue des Frères Lumière